Mangalam Drugs & Organics (NSE:MANGALAM) Moat Score: 0/10 (As of Jul. 05, 2026)


NSE:MANGALAM Mangalam Drugs & Organics Ltd NSE:MANGALAM
47 GF Score
Price ₹28.09
GF Value ₹63.77
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Mangalam Drugs & Organics Moat Score?

Mangalam Drugs & Organics has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Mangalam Drugs & Organics has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Mangalam Drugs & Organics might have No Moat - No discernible moat.

Mangalam Drugs & Organics  (NSE:MANGALAM) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Mangalam Drugs & Organics Moat Score Related Terms

NSE:MANGALAM
47GF Score
Mangalam Drugs & Organics Ltd NSE:MANGALAM
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Mangalam Drugs & Organics (NSE:MANGALAM) Overvalued in 2026?

Based on GuruFocus' analysis, Mangalam Drugs & Organics stock appears to be undervalued. The current stock price of ₹28.09 is trading 56% below its estimated GF Value™ of ₹63.77. GuruFocus considers Mangalam Drugs & Organics to be Possible Value Trap.

Key valuation signals for NSE:MANGALAM:

  • Moat Score: 0
  • GF Value™: ₹63.77 vs. price of ₹28.09 (56% below fair value)
  • GF Score™: 47/100 with 4 warning signs

No single metric tells the full story. See the NSE:MANGALAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mangalam Drugs & Organics Business Description

Other Exchanges 532637:India
Address P. D'Mello Road, Rupam Building, 3rd Floor, No. 239, Near General Post Office, Mumbai, MH, IND, 400001
Mangalam Drugs & Organics Ltd commenced its manufacturing of Active Pharmaceutical Ingredients (APIs) and intermediates. The company is engaged in the manufacture and sale of APIs for various therapeutic segments, including anti-malaria, anti-retroviral, and anti-hypertensive. It is approved by the Bill Clinton Foundation. The company is actively producing Pyronaridine Tetraphosphate, a new API used in antimalarial treatments. The company has received prequalification from the World Health Organization (WHO) for both micronized and non-micronized forms of Pyronaridine Phosphate.
47GF Score

Get the complete analysis for NSE:MANGALAM

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹28.09
Price
₹63.77
GF Value